Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre‐specified subgroup analysis of the randomized CASSINI study

BACKGROUND: Pancreatic cancer patients are at risk for venous thromboembolism (VTE); the value of thromboprophylaxis has not been definitively established. METHODS: This trial randomized cancer patients initiating a new regimen and at high risk for VTE (Khorana score ≥2) to rivaroxaban 10 mg or plac...

Descripción completa

Detalles Bibliográficos
Autores principales: Vadhan‐Raj, Saroj, McNamara, Mairéad G., Venerito, Marino, Riess, Hanno, O'Reilly, Eileen M., Overman, Michael J., Zhou, Xiao, Vijapurkar, Ujjwala, Kaul, Simrati, Wildgoose, Peter, Khorana, Alok A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476843/
https://www.ncbi.nlm.nih.gov/pubmed/32663379
http://dx.doi.org/10.1002/cam4.3269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476843/
https://www.ncbi.nlm.nih.gov/pubmed/32663379
http://dx.doi.org/10.1002/cam4.3269

Ejemplares similares